ABSTRACT Fluvastatin, an amphiphilic anion, shows a nonlinear increase in effective intestinal permeability (P eff ) with increasing lumenal concentrations in rats. The main objective of this study was to investigate whether or not this observation could be attributed to an efflux-mediated transport by the multidrug resistance-associated protein (MRP). In parallel, we investigated the possible involvement of the monocarboxylic acid transporter (MCT) in the rapid intestinal absorption of fluvastatin. Single -pass perfusions were performed in the ileum and colon of the rat, with and without the presence of well-established inhibitors/substrates for the MRP (probenecid) and the MCT (nicotinic acid). The results suggest that neither the MRP nor the MCT are involved to any significant extent in the absorption process of fluvastatin in the rat intestine. Thus, the previously reported concentrationdependent P eff of fluvastatin in these intestinal regions of the rat is probably not attributable to saturation of any efflux mediated by MRP.
INTRODUCTION
Fluvastatin (carboxylic acid; pKa 4.6, log D octanol/buffer pH 6.5 = 1.9) is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. We have previously reported tha t fluvastatin has a high, but concentration-dependent, effective permeability (P eff ) in both the small and the large intestine of the rat (1). The P eff was higher at higher intestinal concentrations, suggesting an effluxmediated transport of fluvastatin by P-glycoprotein (Pgp) and/or multidrug-associated protein (MRP) (1) . This nonlinear Peff was most pronounced in the ileum and the colon (1) . Other inhibitors of HMG-CoA reductase, such as lovastatin acid and atorvastatin, have been reported to be substrates for or inhibitors of Pgp (2) (3) (4) . However, we found that fluvastatin was not transported by Pgp to any significant extent in rats intestine, and th at other mechanism(s) have to be involved instead (1) . For instance, because fluvastatin is surface active, it decreases the surface tension between the lumenal aqueous phase and the intestinal membrane, which may facilitate the absorption at increasing lumenal concentrations. We have previously reported that the colonic Peff of fluvastatin correlates inversely with the surface tension (r 2 = 0.980, P < .05) at lumenal concentrations below the critical micelle concentration of fluvastatin (1 mmol/L) (5) . However, this physicochemical effect could only partially explain the observed concentration-dependent P eff of fluvastatin in rats (5).
Therefore, to further investigate the mechanism behind the concentration-dependent intestinal P eff of fluvastatin, we wanted to investigate the possible involvement of efflux proteins other than Pgp.
MRPs are a family of 190-kDa large -efflux proteins present in many tissues, where they probably function as active transporters of various amphiphilic anions (6) . The MRP family contains at least 6 homologous members, MRP1-6, with partly different tissue distribution in the body. MRP1, MRP2 (cMOAT), and MRP5 are reported to be expressed in the small and/or the large intestine in humans (7, 8) . Based on in vitro experiments with various tissues from rats and humans, MRP1, MRP3, and MRP5 seem to be expressed at the basolateral membrane of cells only (eg, enterocytes) and are transporting in the absorptive direction, whereas MRP2 is expressed at the apical (brush border) membrane and is transporting in the secretive direction (9) . Therefore, of these t ransporters, only MRP2 could be involved in a secretory efflux of drugs into the intestinal lumen. The regional intestinal distribution of MRP2 in rats is contradictory in literature. Gotoh et al reported that the highest expression (mRNA) of MRP2 in the rat intestine is found in the proximal small intestine and the lowest expression in the colon (17) . Makhey et al, on the other hand, reported that the functional intestinal expression (efflux of known substrates) of MRP2 in rats is highest in the colon and the ileum and lower in the jejunum ( 10) . The latter results are in line with our previous findings that the concentration-dependent permeability of fluvastatin is most pronounced in the ileum and the colon of rats (1) . Therefore, our hypothesis is that a member of the MRP family, probably the MRP2, is responsible for the concentration-dependent intestinal P eff of fluvastatin. This hypothesis is also supported by the fact that another inhibitor of HMG-CoA reductase, pravastatin, is transported by the MRP2 in the liver (11, 12) .
The monocarboxylic acid transporter (MCT) in the intestine has been reported to be the predominant mechanism for the uptake of the HMG-CoA reductase inhibitor pravastatin (13) . This transport route was inhibited by several monocarboxylic acids such as acetic acid, benzoic acid, nicotinic acid, lovastatin acid, and simvastatin acid (13) . This process suggests that HMG-CoA reductase inhibitors might also be transported by the MCT. Furthermore, it was recently reported that another HMG-CoA reductase inhibitor, atorvastatin, is transported across Caco-2 cell monolayers by the MCT (14) . Thus, together with passive diffusion, the observed high intestinal P eff of fluvastatin in rats might include active transport across the intestinal mucosa through the MCT. Apparently, fluvast atin belongs to a class of drugs that exhibit complex intestinal absorption mechanisms, involving both passive and active transport in each direction.
The purpose of this study was to investigate the possible involvement of the 2 counteracting transporters, MRP2 and MCT, in the intestinal transport of fluvastatin in rats.
EXPERIMENTAL PROCEDURES

Chemicals
Fluvastatin sodium was provided by AstraZeneca (Mölndal, Sweden). Antipyrine, nicotinic acid, and probenecid were obtained from Sigma Chemicals (St. Louis, MO). 
Study Design
Six groups of rats (n = 4-6, 30 animals in total) were used in this study, which was approved by the Animal Ethics Committee, Uppsala University. The rats were perfused in the ileum or the colon with a perfusion solution containing either 1.6 μmol/L fluvastatin (control), 1.6 μmol/L fluvastatin + 1 μmol/L probenecid, or 1.6 μmol/L fluvastatin + 10 mmol/L nicotinic acid in random order. Only 1 intestinal segment was used in each perfusion experiment and animal. The concentrations of the study compounds/transport inhibitors and physicochemical properties of the 3 perfusion solutions are presented in Table 1 . The molecular structures of fluvastatin, probenecid, and nicotinic acid are shown in Figure 1 . 
Intestinal Single-Pass Perfusions
Male Sprague-Dawley rats, 275-310 g (Crl:CD[SD]BR, Charles River, Uppsala, Sweden) were used. The rats were acclimatized for at least 1 week under controlled conditions (22 to 23°C, 50% air humidity, 12 hours light cycle) before the experiments. They had access to tap water and regular rat chow (R36; Lactamin AB, Stockholm, Sweden) until 14 to 20 hours prior to the experiment, when the chow was withdrawn. The surgery and intestinal perfusions were performed as described previously (1) . In brief, anaesthesia was induced by an intraperitoneal injection of 135 to 150 mg/kg body weight of Inactin-Byk (thiobutabarbital sodium), and the rats were placed on a heating pad to maintain the body temperature at 37 ± 1°C. The abdomen was opened by a midline longitudinal incision and a segment of the ileum (10 cm) or the colon (8 cm) was cannulated with plastic tubing (4 mm outer diameter) and perfused (0.2 mL/minute) for 105 minutes.
Chemical Assays
The concentrations of fluvastatin and antipyrine in the outlet intestinal perfusate were assayed with highperformance liquid chromatography, as described earlier (1, 15) . The perfusate concentrations of 14 Clabelled PEG 4000 and Logan, UT), and a duNoüy interfacial tensiometer (Krüss, Hamburg, Germany), respectively.
Data Analysis
The net water flux (NWF), effective permeability (P eff ), and intestinal radius were calculated from steady-state concentrations in the outlet perfusate as described previously (1) . In brief, the NWF was calculated from the following:
where [PEGin] and [PEGout] are the inlet and outlet concentrations of 14 C-PEG 4000, respectively, and Qin is the inlet flow rate (0.2 mL/minute). The P eff across the intestinal mucosa was calculate d according to the following:
where Cin and Cout are the inlet and outlet (fluid flux corrected) concentrations of the compound investigated, respectively (16) . The intestinal radius was calculated from the length (measured with a thread) and the volume of the segment (amount PEG 4000 in the segment/concentration, PEG 4000 exiting the segment), assuming the segment to have the shape of a cylinder.
The influence of nicotinic acid and probenecid on these transport variables was tested with one-way analysis of variance (StatView; Abacus Concepts, Berkeley, CA). A probability value less than .05 was considered significant. Fisher's least square difference was used to identify significantly different groups. All results are presented as mean values ± SD for 4 to 6 rats.
RESULTS AND DISCUSSION
The possible involvement of an anionic efflux protein (eg, MRP2) in the nonlinear intestinal absorption of fluvastatin in rats was investigated using a singlepass perfusion technique in the ileum and the colon. These 2 intestinal regions have been reported to exhibit the most pronounced concentration-dependent permeability to fluvastatin (1). The MRP2 has been reported to be expressed in both the ileum and the colon of the rat, but at a lower concentration than in the duodenum and the jejunum (17) . On the other hand, Makhey et al reported that the functional expression of MRP2 (ability to efflux known substrates) is highest in the ileum and the colon in rats (10).
Probenecid, an organic anion transport inhibitor, was employed as a substrate/inhibitor of the MRP2. Probenecid has previously been shown to interact directly with, and to inhibit, MRP-mediated transport in in vitro studies with membrane vesicles of MRPoverexpressing cancer cells (18, 19) . In addition, probenecid has been reported to inhibit the intestinal efflux of several organic anions such as cefazolin, phenol red, cephaloridine, and calcein in rats (20) (21) (22) (23) . This inhibitory function suggests that probenecid interacts with the MRP2, which seems to be the only known member of the MRP family that effluxes its substrates into the intestinal lumen (9, 17) . However, in the present study, probenecid (1 mmol/L) had no effect on the transport of fluvastatin (1.6 μmol/L) in the ileum or the colon (Figure 2 ). This lack of effect suggests that fluvastatin is not effluxed to any significant extent by an organic anionic efflux protein, such as the MRP2, in rats in situ. Also, the ileal and colonic Peff of antipyrine and D-glucose were unaffected by the presence of probenecid ( Figure 2) . Thus, the previously reported concentration-dependent P eff of fluvastatin in rats cannot be explained by a saturated efflux-mediated transport by MRP2. To our knowledge, no inhibitors of HMG-CoA reductase have previously been investigated as potential substrates for an intestinal anionic efflux system. In the rat liver, on the other hand, pravastatin is excreted into the bile via the canalicular multispecific organic anionic transporter (cMOAT, MRP2) (11, 12) .
The second aim of this study was to investigate whether or not the MCT is involved in the intestinal absorption of fluvastatin. This transporter is expressed both in the small and in the large intestine (13, 24) . Two inhibitors of HMG-CoA reductase, pravastatin and atorvastatin, are known to be transported across the small intestinal mucosa by this carrier, rather than by simple diffusion (13, 14) . Tamai et al reported that nicotinic acid (10 mmol/L) reduced the uptake of pravastatin across rabbit brush border membrane vesicles by more than 40%; this reduction was attributed to competitive inhibition of the H + -dependent MCT (13) .
In the present study, however, nicotinic acid (10 mmol/L) did not affect the P eff of fluvastatin (1.6 ìmol/L) in the ileum (Figure 2 ). In the colon, on the other hand, the P eff of fluvastatin increased by 37% (P < .05) in the presence of nicotinic acid at the same concentrations as in the ileum (Figure 2) . A possible explanation is that the lower pH of the perfusion solution in the presence of nicotinic acid (pH 6.3 vs 6.5) (Table 1) increased the driving force for the H + -dependent MCT. This hypothesis is supported by data showing that the uptake of pravastatin in rabbit ileal brush border vesicles increased by roughly 30% when the extravesicular pH was decreased from 6.5 to 6.3 (13) . In opposition to this hypothesis is the observation that nicotinic acid did not affect the ileal transport of fluvasta tin in the present study. Thus, the involvement of the MCT in the intestinal transport of fluvastatin seems less probable. This lack of involvement is in accordance with the previously reported increase in the ileal and colonic P eff to fluvastatin in the presence of excess lovastatin, a drug that has been shown to inhibit the MCT (1,13) . Furthermore, the previously reported nonlinear increase in the P eff of fluvastatin at higher lumenal concentrations is not in accordance with a carrier saturated in the absorptive direction (1).
A more feasible explanation for the higher Peff of fluvastatin in the colon at the lower pH, when nicotinic acid was added, is the higher fraction of non-ionized drug at that pH. On the basis of the Henderson-Hasselbalch equation, the fraction of nonionized fluvastatin (acid, pKa 4.6) increased by 58% at pH 6.3 compared to the fraction at pH 6.5. Thus, the increased Peff of fluvastatin at the lower pH might be explained by the increased fraction of non-ionized fluvastatin, according to the pH-partition hypothesis (25) . It is possible that we did not observe this pH effect in the ileum because of the thicker protective mucus and unstirred water layer adjacent to the intestinal wall in this region ( 26) . This layer might have kept the ileal microclimate pH unaffected, despite the slight decrease in the bulk pH. The intestinal P eff of antipyrine and D-glucose was not affected by nicotinic acid (Figure 2 ).
The recovery of the water flux marker 14 C-PEG 4000, the intestinal radius, and the net water flux were unaffecte d by probenecid or nicotinic acid (Table 2) . A high recovery of 14 C-PEG 4000 in the outlet perfusate, stable net water fluxes over time, a high Peff of D-glucose in the ileum, and a low Peff of Dglucose in the colon all indicate that the viability of the intestinal mucosa was maintained in all experiments (Table 2 and Figure 2 ). The results of the present study show that no significant transport interactions between fluvastatin and probenecid and nicotinic acid exist in the rat intestine. Thus, the previously reported concentration-dependent P eff of fluvastatin in these intestinal regions in rats is probably not attributable to saturation of the MRP2 at higher lumenal concentrations of fluvastatin. Because previous results have suggested that the Pgp is not involved in the transport process, the nonlinear P eff of fluvastatin might be caused by an as-yet unknown transport protein in the intestinal epithelium. It is also possible that the previously reported physicochemical interaction between fluvastatin and the intestinal membrane is the major mechanism behind the observed concentration-dependent P eff of fluvastatin in rats ( 5) . Finally, the rapid intestinal absorption of fluvastatin is not mediated by active transport by the MCT to any significant extent. Instead, passive diffusion is probably the dominating absorption mechanism for fluvastatin, which also agrees with its physicochemical properties (27) .
